GlassScriptPhysician profile
Prayus T Tailor
NPI 1679552764
$127,477.28
in general payments reported to CMS, 2019-2025
39 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,347 · 2020: $9,358 · 2021: $33K · 2022: $37K · 2023: $20K · 2024: $22K · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $11K · Food and Beverage: $7,917 · Travel and Lodging: $4,624 · Education: $22.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,600.00 |
| Consulting Fee | $10,600.00 |
| Food and Beverage | $7,916.92 |
| Travel and Lodging | $4,624.25 |
| Education | $22.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $81,536.02 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
| Astrazeneca Pharmaceuticals LP | $13,159.26 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $9,996.79 | 2019-2025 | Nxstage System One, Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $8,202.32 | 2020-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $3,910.49 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $2,774.11 | 2021-2025 | |
| Horizon Therapeutics Plc | $2,203.68 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $811.28 | 2021-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $673.88 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $548.13 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $511.98 | 2019-2025 | |
| Amgen INC. | $499.22 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Calliditas Therapeutics US INC. | $414.72 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $249.61 | 2023-2025 | |
| Daiichi Sankyo INC. | $244.21 | 2019-2025 | Injectafer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $239.09 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $194.37 | 2019-2025 | |
| Akebia Therapeutics INC | $163.67 | 2019-2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $132.10 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Kyowa Kirin, INC. | $116.94 | 2023-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.88 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $88.34 | 2019 | |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
| Ani Pharmaceuticals, INC. | $63.89 | 2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $63.56 | 2019-2023 | Crysvita |
| Opko Pharmaceuticals, LLC | $55.30 | 2019-2020 | |
| Shield Therapeutics INC | $54.50 | 2024 | |
| Amag Pharmaceuticals, INC. | $54.46 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $50.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.66 | 2020-2022 | |
| Inari Medical, INC. | $44.70 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $42.95 | 2025 | Jardiance |
| Mozarc Medical US LLC | $38.17 | 2023 | Argyle |
| Scpharmaceuticals INC. | $23.37 | 2025 | |
| Chiesi USA, INC. | $21.51 | 2025 | Cleviprex |
| Genentech USA, INC. | $16.64 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.83 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.58 | 2021 | |
| Daxor Corporation | $10.16 | 2023 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prayus Tailor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.